PIK3CA assay guides treatment of progressing breast cancer: Katherine Geiersbach, M.D.

from Answers from the Lab · host Mayo Clinic Laboratories

(00:32) Could you provide a little bit of background about yourself, please?(01:01) Please give us a brief overview of the new PIK3CA assay. (02:09) Why do we offer two different tests, and when should each be ordered?(03:58) Which patients should have this testing?(04:39) Is this testing used for patients being considered for second-line treatment after first-line hormone receptor treatment?(05:20) Is there anything else you would like to add about the PIK3CA testing?(06:23) Why is it important to know the molecular signature of these tumors?

Episode metadata supplied by the publisher feed · Published Sep 20, 2022

Embed this episode

Attribution link and audio player

What this episode covers

Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

PIK3CA assay guides treatment of progressing breast cancer: Katherine Geiersbach, M.D.

0:00 8:37

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Answers from the Lab?

This episode is 8 minutes long.

When was this Answers from the Lab episode published?

This episode was published on September 20, 2022.

Can I download this Answers from the Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!